Resource:MATRICS - Measurement And Treatment Research to Improve Cognition in Schizophrenia

From NeuroLex

Resource:MATRICS - Measurement And Treatment Research to Improve Cognition in Schizophrenia

Basic
Advanced

Name:	Resource:MATRICS - Measurement And Treatment Research to Improve Cognition in Schizophrenia
Description:	Cognitive deficits -- including impairments in areas such as memory, attention, and executive function -- are a major determinant and predictor of long-term disability in schizophrenia. Unfortunately, available antipsychotic medications are relatively ineffective in improving cognition. Scientific discoveries during the past decade suggest that there may be opportunities for developing medications that will be effective for improving cognition in schizophrenia. The NIMH has identified obstacles that are likely to interfere with the development of pharmacological agents for treating cognition in schizophrenia. These include: (1) a lack of a consensus as to how cognition in schizophrenia should be measured; (2) differing opinions as to the pharmacological approaches that are most promising; (3) challenges in clinical trial design; (4) concerns in the pharmaceutical industry regarding the US Food and Drug Administration's (FDA) approaches to drug approval for this indication; and (5) issues in developing a research infrastructure that can carry out clinical trials of promising drugs. The MATRICS program will bring together representatives of academia, industry, and government in a consensus process for addressing all of these obstacles. Specific goals of the NIMH MATRICS are: To catalyze regulatory acceptance of cognition in schizophrenia as a target for drug registration. To promote development of novel compounds to enhance cognition in schizophrenia. Leverage economic research power of industry to focus on important but neglected clinical targets. Identify lead compounds and if deemed feasible, support human proof of concept trials for cognition in schizophrenia.
Other Name(s):	Measurement And Treatment Research to Improve Cognition in Schizophrenia, Measurement Treatment Research to Improve Cognition in Schizophrenia
Parent Organization:	University of California at Los Angeles; California; USA
Supporting Agency:	NIMH
Resource Type(s):	Knowledge environment resource
Keywords:	Schizophrenia, Cognitive deficit, Memory, Attention, Executive function, Disability, Cognition, Clinical
Abbreviation:	MATRICS
Resource:	Resource
URL:	http://www.matrics.ucla.edu/index.html
Related condition/disease:	Schizophrenia
Id:	nlx_146271
Link to OWL / RDF:	Download this content as OWL/RDF

Curation status: Curated

For Resource Owners:

A sitemap will keep your NIF Registry description up-to-date and inform search engines about your resource.

Please login to create the sitemap. (top right)

Learn more about what NIF can do for your resource.
Proudly proclaim your inclusion in NIF by displaying the "Registered with NIF" button on your site.

Notes

This page uses this default form:Resource

Contributors

Aarnaud

Facts about Resource:MATRICS - Measurement And Treatment Research to Improve Cognition in SchizophreniaRDF feed

Abbrev	MATRICS +
CurationStatus	curated +
DefiningCitation	http://www.matrics.ucla.edu/index.html  +
Definition	Cognitive deficits -- including impairment … Cognitive deficits -- including impairments in areas such as memory, attention, and executive function -- are a major determinant and predictor of long-term disability in schizophrenia. Unfortunately, available antipsychotic medications are relatively ineffective in improving cognition. Scientific discoveries during the past decade suggest that there may be opportunities for developing medications that will be effective for improving cognition in schizophrenia. The NIMH has identified obstacles that are likely to interfere with the development of pharmacological agents for treating cognition in schizophrenia. These include: (1) a lack of a consensus as to how cognition in schizophrenia should be measured; (2) differing opinions as to the pharmacological approaches that are most promising; (3) challenges in clinical trial design; (4) concerns in the pharmaceutical industry regarding the US Food and Drug Administration's (FDA) approaches to drug approval for this indication; and (5) issues in developing a research infrastructure that can carry out clinical trials of promising drugs. The MATRICS program will bring together representatives of academia, industry, and government in a consensus process for addressing all of these obstacles. Specific goals of the NIMH MATRICS are: To catalyze regulatory acceptance of cognition in schizophrenia as a target for drug registration. To promote development of novel compounds to enhance cognition in schizophrenia. Leverage economic research power of industry to focus on important but neglected clinical targets. Identify lead compounds and if deemed feasible, support human proof of concept trials for cognition in schizophrenia. ept trials for cognition in schizophrenia.
ExampleImage	+
Has default formThis property is a special property in this wiki.	Resource +
Has role	Knowledge environment resource +
Id	nlx_146271 +
Is part of	University of California at Los Angeles; California; USA +
Keywords	Schizophrenia +, Cognitive deficit +, Memory +, Attention +, Executive function +, Disability +, Cognition +, and Clinical +
Label	Resource:MATRICS - Measurement And Treatment Research to Improve Cognition in Schizophrenia +
ModifiedDate	20 June 2012 +
Page has default formThis property is a special property in this wiki.	Resource +
Related disease	Schizophrenia +
SuperCategory	Resource +
Supporting Agency	NIMH +
Synonym	Measurement And Treatment Research to Improve Cognition in Schizophrenia +, and Measurement Treatment Research to Improve Cognition in Schizophrenia +